ALPRESS - ALPRESS - CT 12020 & 12437 - English version

Has

Description

Introduction ALPRESS LP 2.5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 177-5) B/90 tablets (CIP code: 372 965-8) ALPRESS LP 5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 172-3) B/90 tablets (CIP code: 372 966-4) Posted on Mar 19 2013 Active substance (DCI) prazosin base ATC Code C02CA01 Laboratory / Manufacturer PFIZER ALPRESS LP 2.5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 177-5) B/90 tablets (CIP code: 372 965-8) ALPRESS LP 5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 172-3) B/90 tablets (CIP code: 372 966-4) Posted on Mar 19 2013

Sujets

• Hypertension artérielle
• Médecine

Informations

• Publié par: haute-autorite-sante-maladies-vasculaires
• Publié le: 18 juillet 2012
• Nombre de lectures: 43
• Licence : En savoir +
  Paternité, pas d'utilisation commerciale, partage des conditions initiales à l'identique
• Langue: English

Extrait

            

  The legally binding text is the original French version   TRANSPARENCY COMMITTEE

  OPINION   18 July 2012       Examination of the file for proprietary medicinal products registered for a period of 5 years with effect from 26 March 2007 (Official Gazette of 22 April 2008)     ALPRESS LP 2.5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 177-5) B/90 tablets (CIP code: 372 965-8)   ALPRESS LP 5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 172-3) B/90 tablets (CIP code: 372 966-4)     Applicant: PFIZER   prazosin base ATC code : C02CA01 (peripherally acting adrenolytic antihypertensive/alpha blockers)   List I   B/30: Hospitals, National Health Insurance (65%) B/90: National Health Insurance (65%)   Date of Marketing Authorisation (national): 22 June 1988 Amendments of 13 July 2010, 11 July 2011 and 26 August 2011, detailed in the appendix.   Reasons for request :    - Re-assessment of the Actual Benefit following the instruction of 7 May 2011 from the Directorate of Social Security and Directorate-General for Health. - Renewal of inclusion on the list of medicines refundable by National Health Insurance.                   Medical, Economic and Public Health Assessment Division

 

1/12